AmyDTierstenMD

Clinical Trials

• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1997 Jan 01

  Unknown status

  Phase 1, Phase 2

• Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Start of enrollment: 1997 Jan 01

  Completed

  Phase 2

• Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer Start of enrollment: 1997 Feb 01

  Unknown status

  Phase 2

• Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1998 May 01

  Unknown status

  Phase 2

• S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Start of enrollment: 2001 Mar 01

  Completed

  Phase 2

• S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2003 Apr 01

  Terminated

  Phase 2

• Oxaliplatin and Topotecan in Advance Ovarian Cancer Start of enrollment: 2006 Jan 01

  Terminated

  Phase 2

• Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Start of enrollment: 2006 Jun 01

  Completed

  Phase 1

• Irinotecan and Bevacizumab for Recurrent Ovarian Cancer Start of enrollment: 2010 Mar 01

  Completed

  Phase 2

• RAD001 Plus Carboplatin in Breast Cancer Patients Start of enrollment: 2010 Jun 01

  Completed

  Phase 2

• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06

  Active, not recruiting

  Phase 3

• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17

  Completed

  Phase 3

• Comparison of Nutrition Education Alone or With Acupuncture for Weight Loss in Breast Cancer Patients Post-Chemotherapy Start of enrollment: 2014 Sep 01

  Completed

  Not Applicable

• A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22

  Active, not recruiting

  Phase 3

• Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer Start of enrollment: 2015 Dec 16

  Active, not recruiting

  Phase 2

• Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer Start of enrollment: 2016 Mar 01

  Active, not recruiting

  Phase 2

• Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. Start of enrollment: 2016 Oct 01

  Terminated

  Phase 1

• Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Start of enrollment: 2017 Dec 20

  Active, not recruiting

  Phase 1, Phase 2

• Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Start of enrollment: 2018 May 17

  Completed

  Phase 1

• To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer Start of enrollment: 2020 Oct 01

  Withdrawn

  Phase 2

• Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer Start of enrollment: 2024 Oct 01

  Not yet recruiting

  Phase 1, Phase 2

  Roles: Contact, Principal Investigator

• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31

  Recruiting

  Phase 3

  Roles: Contact

• Join now to see all